INTENSITY THERAPEUTICS, INC. INTS
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
3/9
Piotroski F — financial health
-13.31
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$11.6M | — | — | $11.9M |
| 2024 | — | -$16.3M | — | — | $2.9M |
| 2023 | — | -$10.5M | — | — | $13.2M |
| 2022 | — | -$7.6M | — | — | -$15.1M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -13.31 (distress)
- Working capital / assets 0.749
- Retained earnings / assets -5.559
- EBIT / assets -0.849
- Equity / liabilities 5.338
Source: SEC EDGAR filings · CIK 0001567264 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.